INT159982

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 12
Disease Relevance 8.44
Pain Relevance 0.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (ERBB3) extracellular space (ERBB3) extracellular region (ERBB3)
plasma membrane (ERBB3) nucleus (ERBB3)
Anatomy Link Frequency
MDA-MB-231 6
MCF-7 2
ERBB3 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 20 97.12 Very High Very High Very High
COX-2 inhibitor 72 90.96 High High
palliative 3 45.04 Quite Low
imagery 47 13.64 Low Low
Kinase C 18 5.00 Very Low Very Low Very Low
complementary and alternative medicine 6 5.00 Very Low Very Low Very Low
Inflammation 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
withdrawal 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 409 100.00 Very High Very High Very High
Cancer 328 99.84 Very High Very High Very High
Rheumatoid Arthritis 52 99.84 Very High Very High Very High
Apoptosis 432 98.52 Very High Very High Very High
Solid Tumor 5 95.84 Very High Very High Very High
INFLAMMATION 9 95.68 Very High Very High Very High
Fatigue 4 91.08 High High
Stress 7 90.60 High High
Carcinoma 3 88.96 High High
Hyperplasia 4 84.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Therefore, the quantification of FRET between HER2 and HER3, indicating heterodimer formation should be of functional significance and has now been measured in cancer cells by FLIM (Fig. 4a).
Negative_regulation (measured) of HER3 associated with cancer
1) Confidence 0.26 Published 2009 Journal Target Oncol Section Body Doc Link PMC2778706 Disease Relevance 0.65 Pain Relevance 0
Another study demonstrated that RA can induce differentiation of cultured breast tumor cells, and this was again associated with reduction in cell surface HER2 [35]. atRA and 9-cis-RA caused decreases in HER2 and HER3, and inhibited SKBR3 cell growth with cell cycle arrest and induction of apoptosis [36], and the retinoids downregulated HER4 in T47D cells [37]; atRA also downregulated HER2 and HER3 in MCF cells [38]. 4-HPR was reported in another study to downregulate both HER2 and the epidermal growth factor receptor (EGFR, HER1) [39].
Negative_regulation (decreases) of HER3 associated with breast cancer, rheumatoid arthritis and apoptosis
2) Confidence 0.18 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.98 Pain Relevance 0
Another study demonstrated that RA can induce differentiation of cultured breast tumor cells, and this was again associated with reduction in cell surface HER2 [35]. atRA and 9-cis-RA caused decreases in HER2 and HER3, and inhibited SKBR3 cell growth with cell cycle arrest and induction of apoptosis [36], and the retinoids downregulated HER4 in T47D cells [37]; atRA also downregulated HER2 and HER3 in MCF cells [38]. 4-HPR was reported in another study to downregulate both HER2 and the epidermal growth factor receptor (EGFR, HER1) [39].
Negative_regulation (downregulated) of HER3 associated with breast cancer, rheumatoid arthritis and apoptosis
3) Confidence 0.18 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2949655 Disease Relevance 0.93 Pain Relevance 0
Thus, combining pertuzumab with trastuzumab may augment therapeutic benefit by blocking HER2/HER3 signaling.
Negative_regulation (blocking) of HER3
4) Confidence 0.18 Published 2010 Journal Current Genomics Section Body Doc Link PMC2878980 Disease Relevance 0.56 Pain Relevance 0
Celecoxib downregulates COX-2 protein expression in MDA-MB-231 and MDA-MB-435 cells
Negative_regulation (downregulates) of MDA-MB-231 in MDA-MB-231
5) Confidence 0.03 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2206712 Disease Relevance 0.40 Pain Relevance 0.10
In both MDA-MB-231 and MDA-MB-435 cells, COX-2 was suppressed to a greater extent in the E1A transfectants than in the corresponding parental or vector control cells.
Negative_regulation (suppressed) of MDA-MB-231 in MDA-MB-231
6) Confidence 0.03 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2206712 Disease Relevance 0.37 Pain Relevance 0.07
Indeed, COX-2 protein expression was downregulated in all MDA-MB-231 cell variants; the percentage decreases were 32% for the MDA-MB-231 parental cells, 34% for the vector control cells, and 58% for the E1A stable transfectants (Figure 4A).
Negative_regulation (downregulated) of MDA-MB-231 in MDA-MB-231
7) Confidence 0.03 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2206712 Disease Relevance 0.33 Pain Relevance 0.09
This suggests that celecoxib-induced growth inhibition of the highly aggressive MDA-MB-231 cells is independent of PGE2.
Negative_regulation (inhibition) of MDA-MB-231 in MDA-MB-231
8) Confidence 0.01 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1175053 Disease Relevance 0.41 Pain Relevance 0.10
Here, we report that TJ-41 can effectively inhibit hormone sensitive and insensitive breast cancer cell lines (MCF-7 and MDA-MB-231, resp.) and enhance the efficacy of 5-FU.
Negative_regulation (inhibit) of MDA-MB-231 in MDA-MB-231 associated with breast cancer
9) Confidence 0.00 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2730474 Disease Relevance 0.97 Pain Relevance 0
However, it needs much higher concentrations to inhibit MCF-7 and MDA-MB-231 breast cancer cell growth with IC(50) at 22.1microM and 19.6microM, respectively.
Negative_regulation (inhibit) of MDA-MB-231 in MDA-MB-231 associated with breast cancer
10) Confidence 0.00 Published 2009 Journal Biochem. Pharmacol. Section Abstract Doc Link 19428334 Disease Relevance 0.93 Pain Relevance 0.20
Here, we report that TJ-41 can effectively inhibit hormone sensitive and insensitive breast cancer cell lines (MCF-7 and MDA-MB-231, resp.) and enhance the efficacy of 5-FU.
Negative_regulation (inhibit) of MDA-MB-231 in MCF-7 associated with breast cancer
11) Confidence 0.00 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2730474 Disease Relevance 0.97 Pain Relevance 0
However, it needs much higher concentrations to inhibit MCF-7 and MDA-MB-231 breast cancer cell growth with IC(50) at 22.1microM and 19.6microM, respectively.
Negative_regulation (inhibit) of MDA-MB-231 in MCF-7 associated with breast cancer
12) Confidence 0.00 Published 2009 Journal Biochem. Pharmacol. Section Abstract Doc Link 19428334 Disease Relevance 0.93 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox